256951-88-9

Basic information

• Product Name: 4-(3,4-difluorophenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid methyl ester
• CAS NO: 256951-88-9
• Molecular Weight: 282.247
• Mol File: 256951-88-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(3,4-difluorophenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-difluorophenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid methyl ester(256951-88-9)
• EPA Substance Registry System: 4-(3,4-difluorophenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid methyl ester(256951-88-9)

Safety Data

• Hazardous Substances Data: 256951-88-9(Hazardous Substances Data)

Upstream product

• 7424-91-1 methyl 3,3-dimethoxypropionate 
• 34036-07-2 3,4 difluorobenzaldehyde 
• 598-50-5 N-Methylurea 

Downstream Products

• 256951-93-6 (-)-4-(3,4-difluorophenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid 
• 256950-75-1 (-)-4-(3,4-difluorophenyl)-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid 
• 1026319-59-4 (R)-4-(3,4-Difluoro-phenyl)-1,3-dimethyl-2-oxo-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester 
• 256951-90-3 (R)-4-(3,4-Difluoro-phenyl)-1-methyl-2-oxo-3-((R)-1-phenyl-ethylcarbamoyl)-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester 
• 256951-89-0 (S)-4-(3,4-Difluoro-phenyl)-1-methyl-2-oxo-3-((R)-1-phenyl-ethylcarbamoyl)-1,2,3,4-tetrahydro-pyrimidine-5-carboxylic acid methyl ester 
• 256950-74-0 4-(3,4-difluorophenyl)-1-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid 

Relevant articles and documents

Alpha 1A adrenergic receptor antagonists

This invention relates to certain novel compounds and derivatives thereof, their synthesis, and their use as alpha 1a adrenergic receptor antagonists. One application of these compounds is in the treatment of benign prostatic hyperplasia. These compounds are selective in their ability to relax smooth muscle tissue enriched in the alpha 1a receptor subtype without at the same time inducing hypotension. One such tissue is found surrounding the urethral lining. Therefore, one utility of the instant compounds is to provide acute relief to males suffering from benign prostatic hyperplasia, by permitting less hindered urine flow. Another utility of the instant compounds is provided by combination with a human 5-alpha reductase inhibitory compound, such that both acute and chronic relief from the effects of benign prostatic hyperplasia are achieved.